Show 10 5 10 15 20 50 100 250 Sort by year (new to old) Actions News feed Embed this list Save this search Mark all Export Your filters: cql: author="BELCH, A" or (type exact bookEditor and editor="BELCH, A") Mark conference C3 Effect of age on efficacy and safety outcomes in patients with newly diagnosed multiple myeloma receiving lenalidomide and low-dose dexamethasone (RD): the first trial C Hulin, C Shustik, A Belch, MT Petrucci, U Duehrsen, J Lu, K Song, P Rodon, B Pegourie, L Garderet, et al. (2015) HAEMATOLOGICA. 100(suppl. 1). p.152-153 Mark conference C3 CVP plus rituximab compared to CVP alone in previously untreated patients with follicular lymphoma: Impact of baseline prognostic factors K IMRIE, A BELCH, R PETTENGELL, A RUEDA, J MCKENDRICK, P SOLAL-CELIGNY, Fritz Offner (UGent) , I BENCE-BUCKLER, J WALEWSKI, J RAPOSO, et al. (2005) ANNALS OF ONCOLOGY. 16. p.109-110 Mark conference C3 Mabthera (Rituximab) plus CVP chemotherapy for first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma (NHL): Confirmed efficacy with longer follow-up P SOLAL-CELIGNY, K IMRIE, A BELCH, KS ROBINSON, D CUNNINGHAM, A RUEDA, J CATALANO, Fritz Offner (UGent) , J WALEWSKI, J RAPOSO, et al. (2005) BLOOD. 106(11). Mark journalArticle A1 CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma R MARCUS, K IMRIE, A BELCH, D CUNNINGHAM, E FLORES, J CATALANO, P SOLAL-CELIGNY, Fritz Offner (UGent) , J WALEWSKI, J RAPOSO, et al. (2005) BLOOD. 105(4). p.1417-1423 Mark conference C3 An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkins lymphoma R MARCUS, K IMRIE, A BELCH, D CUNNINGHAM, E FLORES, J CATALANO, P SOLAL-CELIGNY, Fritz Offner (UGent) , J WALEWSKI, J RAPOSO, et al. (2003) BLOOD. 102(11).